The test enables differential diagnosis between Crohn’s, ulcerative colitis and irritable bowel syndrome.
Glycominds announced today that it has been awarded the CE Mark (Conformite Europeenne) of the EU for the marketing of the company's IBDX products. The IBDX kit is a series of blood tests for Crohn’s disease, enabling differential diagnosis between Crohn’s disease, ulcerative colitis and irritable bowel syndrome.
The IBDX is the first in a series of cutting-edge blood tests for autoimmune and chronic inflammatory diseases that Glycominds is developing based on the company's proprietary glycomics technology.
Glycominds is developing personalized tests for multiple sclerosis (MS), anti-phospolipid syndrome, rheumatoid arthritis and other diseases. The goal of the company's gMS product for MS to enable earlier diagnosis, and predict whether patients will have clinical or sub-clinical events within the coming months.
At the core of Glycominds’ proprietary biomarker discovery engine is the GlycoChip - an array of diverse glycan molecules attached to a solid surface. This technology is used to identify interactions between the glycans on the chip and antibodies in solution. The GlycoChip recently received Notices of Allowance from the US Patent Office for two major patents to protect this technology.
Published by Globes [online], Israel business news - www.globes.co.il - on Wednesday, May 25, 2005